Praxis Precision Medicines, Inc. (PRAX) |
|
1.475 0.06 (4.24%)
|
09-26 15:33 |
|
Open: |
1.42 |
Pre. Close: |
1.415 |
|
High:
|
1.51 |
Low:
|
1.42 |
|
Volume:
|
317,278 |
Market Cap:
|
190(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 3:21:45 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.84 One year: 2.15 |
| Support: |
Support1: 1.36 Support2: 1.23 |
| Resistance: |
Resistance1: 1.58 Resistance2: 1.84 |
| Pivot: |
1.4 |
| Moving Average: |
MA(5): 1.46  MA(20): 1.42
MA(100): 1.16 MA(250): 1.8 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 60.7 %D(3): 64.5 |
| RSI: |
RSI(14): 56.4 |
| 52-week: |
High: 5.25 Low: 0.79 |
| Average Vol(K): |
3-Month: 947 (K) 10-Days: 1,006 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRAX ] has closed below upper band by 24.3%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.46 - 1.47 |
1.47 - 1.47 |
|
Low:
|
1.36 - 1.37 |
1.37 - 1.38 |
|
Close:
|
1.4 - 1.42 |
1.42 - 1.43 |
|
Company Description |
|
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. |
Headline News |
Tue, 19 Sep 2023
Truist Securities Initiates Coverage of Praxis Precision Medicines ... - Nasdaq
Tue, 19 Sep 2023
APLS, RXT and KLR among pre-market gainers - Seeking Alpha
Tue, 19 Sep 2023
Praxis Precision Medicines (NASDAQ:PRAX) Receives New ... - MarketBeat
Tue, 19 Sep 2023
Praxis Precision Medicines Inc (PRAX) Up 10.56% in Premarket Trading - InvestorsObserver
Wed, 06 Sep 2023
Should Biotechnology Stock Praxis Precision Medicines Inc (PRAX) Be in Your Portfolio Wednesday? - InvestorsObserver
Thu, 31 Aug 2023
Praxis Precision Medicines to Present Data from Epilepsy Portfolio ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
129 (M) |
|
% Held by Insiders
|
7.075e+007 (%) |
|
% Held by Institutions
|
8.3 (%) |
|
Shares Short
|
2,950 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.5938e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-10 |
|
Return on Assets (ttm)
|
914.8 |
|
Return on Equity (ttm)
|
-63.7 |
|
Qtrly Rev. Growth
|
1.46e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-43.8 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-138 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
5.27 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.72e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
